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FIGURE 2. Patent saphenous vein graft–right coronary artery after
rivaroxaban treatment.
Case Report: Cardiaconly a minority of these patients have development of clin-
ically evident HIT.2 Unfortunately, we had no access to
washed-platelet functional assays, such as the carbon 14–
labeled serotonin release assay; nevertheless, our patient
had a high pretest probability for HIT (a score of 7 according
to the 4Ts scoring system3), along with a positive antibody
test result, and so we decided to initiate alternative nonhe-
parin anticoagulation because delays in treatment are asso-
ciated with an initial 5% to 10% daily risk of thrombosis,
amputation, or death. Currently approved parenteral direct
thrombin inhibitors were not available at that time in our
institution, however, and we therefore resorted to using ri-
varoxaban in the management of our patient.
Rivaroxaban is an oral, direct factor X inhibitor that has
shown efficacy in the treatment of venous and arterial
thromboembolism. The key advantages of its use for theFrom the aBrazilian Biosciences National Laboratory, National Center for Research
in Energy and Materials, Campinas, Brazil; and the bDepartment of Surgery, Fac-
ulty of Medical Science, State University of Campinas, Campinas, Brazil.
Disclosures: Authors have nothing to disclose with regard to commercial support.
Received for publication May 5, 2015; accepted for publication May 6, 2015;
available ahead of print June 3, 2015.
Address for reprints: Cesario F. Bianchi, MD, PhD, National Center for Research in
Energy and Materials, Brazilian Biosciences National Laboratory, Rua Giuseppe
Maximo Scolfaro, 10000, Caixa Postal 6192, CEP 13083-970, Campinas, S~ao
Paulo, Brazil (E-mail: cesariobianchi@gmail.com).
J Thorac Cardiovasc Surg 2015;150:e20-2
0022-5223/$36.00
Copyright  2015 by The American Association for Thoracic Surgery
http://dx.doi.org/10.1016/j.jtcvs.2015.05.024
e20 The Journal of Thoracic and Cardiovascular Surgtreatment of HIT include ease of administration (fixed
dose), absence of a need for laboratory monitoring, longer
half-life and lower cost relative to parenteral agents. More-
over, it obviates the need for a warfarin–direct thrombin in-
hibitor overlap period and thus is expected to reduce the
length of hospitalization.4 After initiation of rivaroxaban
treatment, careful attention is necessary, not only to
bleeding but also to potential worsening of thrombocyto-
penia, because there have been rare reports of thrombocyto-
penia with novel oral anticoagulant use.5
Conclusions
This case is one of the first experiences with using rivarox-
aban as an off-label alternative to the standard treatments for
HIT. Although the findings cannot establish the efficacy and
safety of this drug for this indication—a prospective study is
currently being conducted for that purpose4—they seem
promising in the setting of an easier strategy to treat HIT.
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See related article on pages e19-20.Heparin-induced thrombocytopenia (HIT), one of the
immune-mediated thrombocytopenia and thrombosis
disorders, is characterized by a decline in platelet count
between 4 to 14 days (‘‘typical onset’’) after initial exposure
to mainly unfractionated heparin leading to the detection
of anti–platelet factor 4–heparin immune complex IgG
(PF4-Hep-IgG). In patients previously exposed to heparinry c August 2015
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in a few hours,
with HIT devel-
oping in 1 to
2 days (‘‘rapid
onset’’).1 Thisimmune response is atypical, because IgG instead of IgM is
produced after initial exposure, antibody titers disappear
after 90 to 120 days, and most patients later re-exposed to
heparin do not have antibody titers developed again.
PF4-Hep-IgG activates platelet FcgRIIA receptors,
releasing thrombin and further activating platelets,
monocytes, and endothelial cells, with the formation of
fibrin leading to highly prothrombotic states. Sites of
vascular injury and atherosclerosis become particularly
prone to thrombus formation.1,2
HIT remains a difficult clinical problem because the
unique laboratory tests necessary for a conclusive diagnosis
are seldom available. Clinicians often have to make
decision on a ‘‘suspected’’ case of HIT by using the 4Ts
or the HIT Expert Probability clinical scoring systems and
the laboratory detection and quantitation of specific IgG
polyclonal antibodies against heparin–platelet factor 4
complex.
In this issue of the Journal, Abouchakra and colleagues3
have reported an off-label treatment with rivaroxaban
(a Factor Xa inhibitor), one of the novel oral anticoagulants,
for a suspected case of HIT after cardiac surgery. Readers
should be aware of and consider carefully some important
points.
Although thrombocytopenia is an essential part of the
diagnosis, it rarely causes bleeding. It is the associated
prothrombotic state that needs serious attention.
Two major clinical points, however, must be fulfilled
to characterize HIT: (1) the thrombotic events have to
occur with concomitant thrombocytopenia, and (2) the
timing of thrombocytopenia and thrombosis must be
related to the heparin therapy. The first point occurs
more frequently in sites of vascular injury, with the
venous territories being the lower limb and deep venous
thrombosis and pulmonary embolism being the predom-
inant complications.1 The initial presentation of this pa-
tient was chest pain with a diagnosis of a thrombus in
the saphenous vein graft to the right coronary artery
(vascular injury) by coronary angiography and another
thrombus in the carotid bulb (possibly atherosclerosis?)
by ultrasonographic examination. The second point is
that the timely exposure to heparins should correlate
with the clinical findings for each HIT case. Abou-
chakra and colleagues’ report does not provide aof Thoracic and Cadetailed description regarding previous heparin exposure
before the heart surgery, which is important for a
conclusive diagnostic of HIT. Their patient had several
other factors that could have caused a drop in platelet
count, such as the use of aspirin, clopidogrel, and enox-
aparin; device exposure (such as the oxygenator
membrane); infections; and antibiotics. These factors,
which are not mentioned in this case report, may have
induced the thrombocytopenia.
Readers should also be aware that the immunoassay for
anti–platelet factor 4 antibody levels (mentioned in this
case report), despite being highly sensitive (about 99%),
is not specific for HIT (>40%) because anti–platelet
factor 4 antibodies can be present without HIT.1,4,5 A
washed-platelet activation assay (not available to
Abouchakra and colleagues) is not by itself sufficient
to confirm the diagnosis. Both IgG antibodies and a
functional activation assay are necessary for a conclusive
diagnosis.
After the diagnosis of HIT was considered, Abouchakra
and colleagues note that lepirudin was not available (it
was discontinued by the manufacturer in 2012) and give
this as the reason to use rivaroxaban. Abouchakra and
colleagues mention argatroban and danaparoid sodium as
treatment options but do not mention fondaparinux
sodium (an off-label factor Xa inhibitor), which is often
available, easy to administer, low cost, and shown to
have a good safety profile.6 Fondaparinux sodium,
however, may not work in every patient and may even cause
HIT.7,8
Despite the issues raised here, rivaroxaban remains an
off-label treatment option because of its single daily
dose and the apparent lack of a need for monitoring the
levels of factor Xa inhibition.9 In addition, rivaroxaban
has already been used successfully in patients with
HIT.10 Because rivaroxaban partially depends on renal
clearance, its use in patients with renal impairment should
be limited. It also has potential interactions with strong in-
hibitors of cytochrome P-450 and cytochrome P-450 3A4
and with permeability glycoprotein, and there is no
antidote.9,11
An ongoing clinical trial (NCT01598168) is expected to
present substantial results regarding the use of rivaroxaban
in patients with HIT by 2016,9 guiding us to a more
scientifically driven decision on the use of this drug.
The most important action in patients with highly
suspected HIT is avoiding contact with any heparin type
after the diagnosis has been made. Long-term treatment is
also critical after initial therapy. A minimum of 4 weeks
of anticoagulation therapy with a nonheparin anticoagulant
is the therapeutic target, even after the platelet count has
increased.1
Future HIT clinical managements may include inhibition
downstream of the platelet FcgRIIA receptor signaling andrdiovascular Surgery c Volume 150, Number 2 e21
Editorial Commentary Bianchi and Petrucciidentification of genetic markers that will predict a patient’s
likelihood of HIT-related thrombosis.12,13
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